文献速递冠心病

极高危非ST段抬高型急性冠脉综合征的极早期侵入策略:RAPID NSTEMI试验

Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trial.
PubMed 文献 · Heart · 2024-03-12

RAPID NSTEMI为多中心随机对照试验,纳入GRACE 2.0评分≥118或≥90且伴至少一项高危特征的高危NSTE-ACS患者,比较极早期侵入策略(随机后<90分钟)与标准侵入策略(<72小时)。12个月主要复合终点(全因死亡、新发心梗或心衰住院)在两组间无显著差异(5.9% vs 6.7%,OR 0.93,95%CI 0.42–2.09,p=0.86),极早期组住院时间缩短。

要点

  • 极早期侵入策略未改善12个月临床复合终点。
  • 极早期组住院时间较标准组缩短(3.9天 vs 6.3天,p<0.01)。
  • 试验因招募缓慢提前终止,主要终点事件率低,检验效能不足。

核心结论

  • 在高危NSTE-ACS患者中,极早期侵入策略与标准侵入策略相比未改善12个月临床结局。
  • 主要终点事件率低且试验检验效能不足,无法排除组间差异。

研究设计与样本

  • 多中心、随机、对照、实用性策略试验。
  • 纳入高危NSTE-ACS患者,定义为GRACE 2.0评分≥118,或≥90且至少伴一项额外高危特征。
  • 随机分配至极早期侵入策略(随机后<90分钟)或标准侵入策略(<72小时)。
  • 共随机425例,其中413例接受侵入策略:极早期组204例,标准组209例。
  • 因COVID-19疫情期间招募缓慢,试验由资助方提前终止。

主要发现

  • 极早期组随机至侵入中位时间1.5小时(IQR 0.9–2.0),标准组44.0小时(IQR 22.9–72.6)。
  • 12个月主要复合终点(全因死亡、新发心梗或心衰住院)极早期组5.9%,标准组6.7%(OR 0.93,95%CI 0.42–2.09;p=0.86)。
  • 卒中及大出血发生率两组相似。
  • 极早期组住院时间缩短(3.9天(SD 6.5) vs 6.3天(SD 7.6),p<0.01)。

临床怎么用

  • 对于高危NSTE-ACS患者,极早期侵入策略未显示临床终点获益,不支持常规将侵入时间压缩至90分钟内。
  • 极早期策略可缩短住院时间,但需结合主要终点无差异及试验效能不足解读。

局限性

  • 试验因招募缓慢提前终止,样本量425例,检验效能不足。
  • 主要终点事件率低,可能影响组间差异的检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether a very early invasive strategy (IS)±revascularisation improves clinical outcomes compared with standard care IS in higher risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: Multicentre, randomised, controlled, pragmatic strategy trial of higher risk patients with NSTE-ACS, defined by Global Registry of Acute Coronary Events 2.0 score of ≥118, or ≥90 with at least one additional high-risk feature. Participants were randomly assigned to very early IS±revascularisation (<90 min from randomisation) or standard care IS±revascularisation (<72 hours). The primary outcome was a composite of all-cause mortality, new myocardial infarction or hospitalisation for heart failure at 12 months. RESULTS: The trial was discontinued early by the funder due to slow recruitment during the COVID-19 pandemic. 425 patients were randomised, of whom 413 underwent an IS: 204 to very early IS (median time from randomisation: 1.5 hours (IQR: 0.9-2.0)) and 209 to standard care IS (median: 44.0 hours (IQR: 22.9-72.6)). At 12 months, there was no significant difference in the primary outcome between the early IS (5.9%) and standard IS (6.7%) groups (OR 0.93, 95% CI 0.42 to 2.09; p=0.86). The incidence of stroke and major bleeding was similar. The length of hospital stay was reduced with a very early IS (3.9 days (SD 6.5) vs 6.3 days (SD 7.6), p<0.01). CONCLUSIONS: A strategy of very early IS did not improve clinical outcomes compared with a standard care IS in higher risk patients with NSTE-ACS. However, the primary outcome rate was low and the trial was underpowered to detect such a difference. TRIAL REGISTRATION NUMBER: NCT03707314.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kite, Ladwiniec, Greenwood, et al. Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trial. Heart. 2024. PMID: 38103913. doi:10.1136/heartjnl-2023-323513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。